Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection

Target: MAPT Composite Score: 0.751 Price: $0.66▲31.4% Citation Quality: Pending neuroscience Status: proposed Variant of Cholinergic Basal Forebrain-Hippocampal Circuit Pr

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🧠 Neurodegeneration 🟢 Parkinson's Disease

🏆 ChallengeSolve: Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection$125K bounty →

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

B+

Composite: 0.751

Top 9% of 1875 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

A Mech. Plausibility 15% 0.80 Top 14%

B Evidence Strength 15% 0.65 Top 29%

B+ Novelty 12% 0.75 Top 32%

B+ Feasibility 12% 0.70 Top 36%

B+ Impact 12% 0.72 Top 47%

C+ Druggability 10% 0.55 Top 50%

B Safety Profile 8% 0.60 Top 34%

A Competition 6% 0.80 Top 23%

B+ Data Availability 5% 0.75 Top 26%

B Reproducibility 5% 0.65 Top 36%

Evidence

13 supporting | 4 opposing

Citation quality: 85%

Debates

18 sessions B

Avg quality: 0.61

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Circuit-level neural dynamics in neurodegeneration

Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit disruption, (2) cortical dynamics alterations, (3) sensory processing changes. Identify circuit-based therapeutic targets connecting genes, proteins, and brain regions to neurodegeneration phenotypes.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale The dopaminergic ventral tegmental-hippocampal circuit protection hypothesis centers on the MAPT gene's tau protein and its selective vulnerability in VTA dopaminergic neurons due to their unique metabolic and anatomical properties. Hyperphosphorylated tau accumulates preferentially in VTA neurons because dopamine metabolism generates excessive reactive oxygen species through monoamine oxidase activity, creating a pro-aggregation environment that promotes tau misfolding and microtubule destabilization. This pathological tau disrupts axonal transport mechanisms essential for vesicular dopamine packaging and receptor trafficking, specifically interfering with kinesin and dynein motor proteins that depend on intact microtubule networks. The cascade progresses as impaired vesicular transport compromises dopaminergic neurotransmission to hippocampal targets, disrupting D1/D5 receptor-mediated cAMP-PKA signaling and D2 receptor-mediated inhibitory pathways that normally modulate synaptic plasticity and memory formation. ## Preclinical Evidence Transgenic mouse models expressing human P301S tau mutations demonstrate early tau pathology in VTA dopaminergic neurons, with immunohistochemical studies showing AT8-positive tau aggregates appearing 2-3 months before cortical involvement. Post-mortem analyses of human AD brains reveal significant dopaminergic denervation in the ventral hippocampus correlating with Braak tau staging, while microdialysis studies in tau transgenic mice show reduced dopamine release in hippocampal subfields during memory tasks. Cell culture experiments using primary VTA neurons transfected with mutant tau show impaired vesicular transport of fluorescently-labeled dopamine vesicles and reduced tyrosine hydroxylase trafficking to axon terminals. Optogenetic stimulation studies in tau transgenic mice demonstrate disrupted VTA-hippocampal theta synchronization during spatial learning tasks, with restoration of circuit function through dopaminergic agonist treatment. ## Therapeutic Strategy Therapeutic intervention could target multiple nodes in this pathway, including tau aggregation inhibitors specifically designed to penetrate dopaminergic neurons, such as methylene blue derivatives or small molecule tau disaggregators delivered via focused ultrasound to enhance blood-brain barrier permeability in the VTA region. Dopaminergic replacement strategies using L-DOPA prodrugs or selective D1/D5 receptor agonists could bypass upstream tau pathology to restore hippocampal dopaminergic tone and synaptic plasticity. Neuroprotective approaches might include mitochondrial-targeted antioxidants like MitoQ to reduce oxidative stress in VTA neurons, or microtubule-stabilizing agents such as epothilone D analogs to counteract tau-mediated cytoskeletal disruption. Gene therapy approaches using adeno-associated virus vectors could deliver tau-targeting microRNAs or promote endogenous tau clearance through enhanced autophagy-lysosomal pathways specifically in dopaminergic neurons. ## Biomarkers and Endpoints Key biomarkers would include CSF dopamine metabolite ratios (DOPAC/dopamine) as indicators of VTA dysfunction, combined with tau PET imaging using tracers like [18F]MK-6240 to assess tau burden specifically in brainstem regions. Functional endpoints could involve quantitative EEG measures of VTA-hippocampal coherence during memory tasks, alongside cognitive assessments focused on episodic memory and spatial navigation that specifically depend on this circuit. Advanced neuroimaging techniques such as neuromelanin-sensitive MRI could track dopaminergic neuron loss in the VTA longitudinally as a progression biomarker. ## Potential Challenges The primary challenge lies in achieving selective therapeutic targeting of VTA dopaminergic neurons without affecting other dopaminergic systems like the nigrostriatal pathway, which could lead to parkinsonian side effects. Blood-brain barrier penetration represents a significant hurdle, particularly for large molecule tau aggregation inhibitors, requiring advanced delivery systems or invasive procedures that may limit clinical feasibility. Off-target effects on other neurotransmitter systems, especially given dopamine's broad physiological roles in reward, motivation, and motor control, could produce psychiatric or movement-related adverse events that complicate clinical development. ## Connection to Neurodegeneration This mechanism directly contributes to Alzheimer's disease pathogenesis by establishing tau pathology as the primary driver of circuit-specific neurodegeneration, explaining why memory impairment often precedes other cognitive deficits in AD patients. The selective vulnerability of the VTA-hippocampal dopaminergic system provides a mechanistic link between tau accumulation and the characteristic hippocampal atrophy observed in early-stage Alzheimer's disease. Furthermore, disruption of this neuromodulatory circuit creates a cascade of synaptic dysfunction that may render hippocampal neurons more susceptible to subsequent amyloid-beta toxicity, suggesting that dopaminergic denervation serves as a critical early event in AD neurodegeneration." Framed more explicitly, the hypothesis centers MAPT within the broader disease setting of neuroscience. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating MAPT or the surrounding pathway space around dopaminergic signaling pathway can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.65, novelty 0.75, feasibility 0.70, impact 0.72, and mechanistic plausibility 0.80. ## Molecular and Cellular Rationale The nominated target genes are `MAPT` and the pathway label is `dopaminergic signaling pathway`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of MAPT or dopaminergic signaling pathway is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance. Identifier 31285742. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Hippocampal interneurons shape spatial coding alterations in neurological disorders. Identifier 40392508. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. Identifier 41642658. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. Identifier 41804841. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. Identifier 41767305. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. Identifier 41822813. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. Identifier 41931258. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Viral and non-viral cellular therapies for neurodegeneration. Identifier 41585268. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. Identifier 41619411. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. Identifier 41828591. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7506`, debate count `3`, citations `17`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAPT in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting MAPT within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers MAPT within the broader disease setting of neuroscience. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating MAPT or the surrounding pathway space around dopaminergic signaling pathway can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.65, novelty 0.75, feasibility 0.70, impact 0.72, and mechanistic plausibility 0.80.

Molecular and Cellular Rationale

The nominated target genes are `MAPT` and the pathway label is `dopaminergic signaling pathway`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of MAPT or dopaminergic signaling pathway is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance. Identifier 31285742. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Hippocampal interneurons shape spatial coding alterations in neurological disorders. Identifier 40392508. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. Identifier 41642658. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. Identifier 41804841. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. Identifier 41767305. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. Identifier 41822813. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. Identifier 41931258. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Viral and non-viral cellular therapies for neurodegeneration. Identifier 41585268. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. Identifier 41619411. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. Identifier 41828591. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7506`, debate count `3`, citations `17`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAPT in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting MAPT within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["MAPT gene
expression"]
    B["Tau protein
production"]
    C["Hyperphosphorylated
tau accumulation"]
    D["Locus coeruleus
neurons"]
    E["Microtubule
destabilization"]
    F["Axonal transport
impairment"]
    G["Norepinephrine
release reduction"]
    H["Hippocampal
noradrenergic
denervation"]
    I["Synaptic plasticity
dysfunction"]
    J["Neuroinflammation
activation"]
    K["Cellular stress
response failure"]
    L["Hippocampal tau
pathology spread"]
    M["Memory and
cognitive decline"]
    N["Noradrenergic
replacement therapy"]
    O["Tau aggregation
inhibitors"]

    A -->|"transcription"| B
    B -->|"pathological
modification"| C
    C -->|"selective
vulnerability"| D
    D -->|"tau toxicity"| E
    E -->|"transport
disruption"| F
    F -->|"neurotransmitter
depletion"| G
    G -->|"circuit
disconnection"| H
    H -->|"loss of
modulation"| I
    H -->|"reduced
anti-inflammatory"| J
    H -->|"impaired
neuroprotection"| K
    I -->|"functional
decline"| M
    J -->|"tissue
damage"| L
    K -->|"vulnerability
increase"| L
    L -->|"progressive
pathology"| M
    N -->|"circuit
restoration"| H
    O -->|"tau
reduction"| C

    classDef normal fill:#4fc3f7
    classDef therapeutic fill:#81c784
    classDef pathology fill:#ef5350
    classDef outcome fill:#ffd54f
    classDef molecular fill:#ce93d8

    class A,B,D,G molecular
    class E,F,I,K normal
    class C,H,J,L pathology
    class M outcome
    class N,O therapeutic

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

17 citations 17 with PMID Validation: 85% 13 supporting / 4 opposing

✓ For (13)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 6CLIN 7GENE 4EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Early electrophysiological disintegration of hippo…	Supporting	GENE	-	-	-	-	PMID:31285742	-
Hippocampal interneurons shape spatial coding alte…	Supporting	MECH	-	-	-	-	PMID:40392508	-
TP53/TAU axis regulates microtubule bundling to co…	Supporting	MECH	J Clin Invest	-	2026	-	PMID:41642658	-
Genetic architecture of plasma pTau217 and related…	Supporting	CLIN	Alzheimers Deme…	-	2026	-	PMID:41804841	-
Differential genome-wide association analysis of s…	Supporting	GENE	Front Genet	-	2026	-	PMID:41767305	-
Shared genetic architecture between Parkinson'…	Supporting	GENE	Sleep Adv	-	2026	-	PMID:41822813	-
Spontaneous tauopathy with parkinsonism in an aged…	Supporting	MECH	Front Aging Neu…	-	2026	-	PMID:41695270	-
Progressive Supranuclear Palsy-A Global Review.	Supporting	CLIN	Mov Disord Clin…	-	2026	-	PMID:40898879	-
Alzheimer's disease basics: we all should kno…	Supporting	MECH	Neurol Res	-	2026	-	PMID:40639927	-
Predicting onset of symptomatic Alzheimer's d…	Supporting	CLIN	Nat Med	-	2026	-	PMID:41714746	-
NAD(+) restores proteostasis through splicing-depe…	Supporting	MECH	Autophagy	-	2026	-	PMID:41313318	-
A minimally invasive dried blood spot biomarker te…	Supporting	CLIN	Nat Med	-	2026	-	PMID:41491101	-
Plasma pTau 217/β-amyloid 1-42 ratio for enhanced …	Supporting	GENE	Brain	-	2026	-	PMID:41562409	-
CRISPR-Cas9 and next-generation gene editing strat…	Opposing	CLIN	Acta Neurol Bel…	-	2026	-	PMID:41931258	-
Viral and non-viral cellular therapies for neurode…	Opposing	MECH	Front Med (Laus…	-	2025	-	PMID:41585268	-
Experimental and translational models of Alzheimer…	Opposing	CLIN	J Prev Alzheime…	-	2026	-	PMID:41619411	-
Astroglial and Neuronal Injury Markers (GFAP, UCHL…	Opposing	CLIN	Int J Mol Sci	-	2026	-	PMID:41828591	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 13

Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seedi…▼

PMID:31285742

Hippocampal interneurons shape spatial coding alterations in neurological disorders

PMID:40392508

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.

J Clin Invest · 2026 · PMID:41642658

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide associati…▼

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.

Alzheimers Dement · 2026 · PMID:41804841

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies o…▼

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus.

Front Genet · 2026 · PMID:41767305

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the …▼

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17.

Sleep Adv · 2026 · PMID:41822813

Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.

Front Aging Neurosci · 2026 · PMID:41695270

Progressive Supranuclear Palsy-A Global Review.

Mov Disord Clin Pract · 2026 · PMID:40898879

Alzheimer's disease basics: we all should know.

Neurol Res · 2026 · PMID:40639927

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Nat Med · 2026 · PMID:41714746

NAD(+) restores proteostasis through splicing-dependent autophagy.

Autophagy · 2026 · PMID:41313318

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.

Nat Med · 2026 · PMID:41491101

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathol…▼

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain · 2026 · PMID:41562409

✗ Opposing Evidence 4

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative path…▼

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.

Acta Neurol Belg · 2026 · PMID:41931258

Viral and non-viral cellular therapies for neurodegeneration.

Front Med (Lausanne) · 2025 · PMID:41585268

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insi…▼

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights.

J Prev Alzheimers Dis · 2026 · PMID:41619411

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers…▼

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders.

Int J Mol Sci · 2026 · PMID:41828591

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Hypothesis Debate | 6 rounds | 2026-04-27 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistic Analysis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PVALB in Early MCI

Critical Evaluation of Mechanistic Rationale

1. Foundational Claim: PV+ Interneurons as Gamma Pacemakers

The hypothesis correctly identifies parvalbumin-positive (PV+) fast-spiking interneurons as critical for gamma oscillation generation in hippocampal CA1. This is well-supported by extensive literature:

Buzsáki & Wang (2012) established the "interneuron network gamma" (ING) mechanism where PV+ cells synchronize through electrical coupling and rebound excitation
**Cardin et a

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Rigorous Skeptic's Critique: tFUS + 40Hz Gamma Entrainment Targeting PVALB in Early MCI

1. Weakest Assumptions

A. Mechanistic Specificity of tFUS → Ion Channel Cascade

Critical flaw: The hypothesis claims tFUS directly activates Nav1.1, Cav2.1, Cav1.3, Piezo1, and TREK-1 to trigger a specific molecular cascade. This assumes:

Mechanical forces from tFUS can selectively activate voltage-gated ion channels (designed for electrical, not mechanical, stimuli)

The downstream CaMKII → AMPA receptor phosphorylation occurs specifically in PV+ interneurons

This cascade is suff

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Translational Feasibility Assessment

Hypothesis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PV+ Interneuron Dysfunction in Early MCI

1. Target Druggability and Accessibility Assessment

Target Identification:

PVALB encodes parvalbumin, a calcium-binding protein that defines a distinct GABAergic interneuron subclass
PVALB itself is not directly druggable—it is a structural protein, not an enzyme or receptor
The actual functional target is PV+ interneuron activity and resulting 40Hz gamma oscillations

Accessibility with Existing Tools:

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Synthesized Assessment: Closed-Loop tFUS with 40Hz Gamma Entrainment for Early MCI

Five-Dimensional Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Plausibility | 0.82 | The PV+ interneuron → gamma oscillation link is robustly established (Cardin et al., PMID:19339603; Buzsáki & Wang, 2012). However, the hypothesis overstates mechanistic precision by claiming direct activation of specific voltage-gated channels (Nav1.1, Cav2.1, Cav1.3) via tFUS. Evidence for mechanosensitive activation of these channels remains indirect. |
| **Evidence Str

Price History

7d Trend

↘

Falling

7d Momentum

▼ 11.8%

Volatility

Medium

0.0272

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
⚖	Recalibrated	$0.503	▼ 1.1%	market_dynamics	2026-04-13 03:33
📄	New Evidence	$0.508	▲ 2.2%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.498	▲ 2.6%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.485	▲ 0.9%		2026-04-12 18:34
⚖	Recalibrated	$0.481	▲ 1.0%		2026-04-12 10:15
⚖	Recalibrated	$0.476	▼ 1.1%		2026-04-10 15:58
⚖	Recalibrated	$0.482	▼ 4.7%		2026-04-10 15:53
📄	New Evidence	$0.505	▼ 8.1%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.550	▲ 15.5%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.476	▼ 0.6%		2026-04-08 22:18
⚖	Recalibrated	$0.479	▲ 53.4%		2026-04-08 18:39
💬	Debate Round	$0.312	▼ 36.7%	market_dynamics	2026-04-07 16:49
💬	Debate Round	$0.493	▼ 16.6%	market_dynamics	2026-04-07 16:41
📄	New Evidence	$0.592	▼ 1.4%	market_dynamics	2026-04-07 14:55
💬	Debate Round	$0.600	▲ 10.6%	market_dynamics	2026-04-07 14:39

Clinical Trials (5) Relevance: 68%

0
Active

0
Completed

0
Total Enrolled

PHASE1
Highest Phase

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS) Unknown

COMPLETED · NCT03718494 · Mayo Clinic

Alzheimer Dementia

Brain Magnetic Resonance Imaging (MRI) F-18 Florbetapir Positron Emission Tomography (PET) Imaging F-18 AV-1451 Positron Emission Tomography (PET) Imaging

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum PHASE2

TERMINATED · NCT02406027 · Janssen Research & Development, LLC

Alzheimer Disease

JNJ-54861911, 10 mg JNJ-54861911, 25 mg Placebo

Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease Unknown

COMPLETED · NCT06224920 · Ludwig-Maximilians - University of Munich

Alzheimer Disease Corticobasal Syndrome

magnetic resonance imaging electroencephalography blood and CSF biomarker

Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease PHASE2

COMPLETED · NCT05423522 · Medesis Pharma SA

Alzheimer's Disease

NanoLithium® NP03 Placebo

A Noval Tau Tracer in Young Onset Dementia PHASE1

UNKNOWN · NCT04248270 · Chang Gung Memorial Hospital

Alzheimer's Disease Vascular Dementia Dementia

18F-PM-PBB3

📚 Cited Papers (18)

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain (2026) · PMID:41562409

3 figures

Figure 1

Discriminatory performance of plasma pTau217 and the pTau217/Aβ 1–42 ratio for prediction of amyloid PET + CSF positivity . Receiver operating characteristic (ROC) curves for plas...

pmc_api

Figure 2

Distributional validation and parametric estimation of diagnostic performance for plasma pTau217. Quantile–quantile plots of plasma pTau217 values in amyloid-positive ( A ) and am...

pmc_api

Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease.

Neural plasticity (2020) · PMID:31285742

No extracted figures yet

Hippocampal Interneurons Shape Spatial Coding Alterations in Neurological Disorders.

Molecular neurobiology (2025) · PMID:40392508

No extracted figures yet

Alzheimer's disease basics: we all should know.

Neurological research (2026) · PMID:40639927

No extracted figures yet

Progressive Supranuclear Palsy-A Global Review.

Movement disorders clinical practice (2026) · PMID:40898879

No extracted figures yet

NAD+ restores proteostasis through splicing-dependent autophagy.

Autophagy (2026) · PMID:41313318

No extracted figures yet

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.

Nat Med (2026) · PMID:41491101

No extracted figures yet

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain (2026) · PMID:41562409

No extracted figures yet

Viral and non-viral cellular therapies for neurodegeneration.

Frontiers in medicine (2025) · PMID:41585268

No extracted figures yet

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights.

J Prev Alzheimers Dis (2026) · PMID:41619411

No extracted figures yet

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.

J Clin Invest (2026) · PMID:41642658

No extracted figures yet

Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.

Front Aging Neurosci (2026) · PMID:41695270

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Circuit-level neural dynamics in neurodegeneration — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-26abc5e5f9f2. Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit di …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

mutate · gen 2

parent: h-var-f687d4593b

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.70

43.4th percentile (776 hypotheses)

Tokens Used

9,494

KG Edges Generated

1,929

Citations Produced

Cost Ratios

Cost per KG Edge

88.73 tokens

Lower is better (baseline: 2000)

Cost per Citation

558.47 tokens

Lower is better (baseline: 1000)

Cost per Score Point

14974.76 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.070

10% weight of efficiency score

Adjusted Composite

0.821

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-17T09:10	$0.686	0.538

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (130)

40Hz gamma entrainment APOE APOE4 APP AQP4 Alzheimer's disease Alzheimer's disease pathology BDNF CA1 CA3 CAMK2A CDK5 CHAT CSF1R CaMKII CaMKII_protein Closed-loop tACS EC layer II SST interneurons Entorhinal cortex layer II GABAergic interneuron networks

Dependency Graph (1 upstream, 0 downstream)

Depends On

Locus Coeruleus-Hippocampal Circuit Protectionrefines (0.5)

Linked Experiments (9)

Related Hypotheses

Glymphatic-Mediated Tau Clearance Dysfunction

Score: 0.865 | neuroscience

Dual-Circuit Tau Vulnerability Cascade

Score: 0.774 | neuroscience

Cholinergic Basal Forebrain-Hippocampal Circuit Protection

Score: 0.760 | neuroscience

Repeat-domain exposure defines seed-competent tau conformers

Score: 0.760 | neurodegeneration

Tau dysfunction destabilizes labile pool

Score: 0.750 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

4.5 years

🧪 Falsifiable Predictions (4)

4 total 0 confirmed 0 falsified

IF tau hyperphosphorylation is selectively reduced in VTA dopaminergic neurons via targeted inhibitor (e.g., lithium, GSK-3β inhibitor) in P301S tau transgenic mice THEN hippocampal dopamine release measured by microdialysis during spatial memory tasks will increase to wild-type levels and theta-gamma coupling during learning will normalize using P301S tau transgenic mice crossed with DAT-Cre mice for cell-type specificity

pending conf: 0.50

Expected outcome: Hippocampal dopamine concentration will increase by ≥40% and VTA-hippocampal theta synchronization will be restored to ≥80% of wild-type levels during Barnes maze testing

Falsified by: If selective reduction of tau hyperphosphorylation in VTA neurons does NOT restore hippocampal dopamine release and theta synchronization, the hypothesis that tau-mediated transport disruption causes dopaminergic dysfunction is disproven. Wild-type mice should show no further improvement.

Method: VTA-targeted injection of AAV-Cre in P301S/flox-tau mice to delete tau selectively in dopaminergic neurons, followed by in vivo microdialysis and local field potential recordings during spatial memory tasks

IF microtubule-stabilizing agent (e.g., epothilone D) is administered to P301S tau mice THEN vesicular dopamine transport velocity in VTA axons measured by fluorescent VMAT2-pHluorin imaging will normalize and D1 receptor density in hippocampal terminals will increase using primary VTA neuronal cultures from P301S transgenic mice

pending conf: 0.50

Expected outcome: Vesicular transport velocity will increase from <0.5 μm/s to ≥1.2 μm/s (wild-type baseline) and D1 receptor fluorescence in hippocampal mossy fiber terminals will increase by ≥50%

Falsified by: If microtubule stabilization does NOT restore vesicular transport velocity and D1 receptor trafficking in VTA neurons, then tau disruption of microtubule-based transport is NOT the primary mechanism of dopaminergic dysfunction, disproving this specific pathway

Method: Live-cell imaging of primary VTA neurons using VMAT2-pHluorin and D1-mCherry reporters with quantitative trafficking analysis before and after epothilone D treatment (100 nM, 24h)

IF tau phosphorylation is reduced via GSK3β inhibition (e.g., lithium or small molecule inhibitors) in P301S MAPT transgenic mice THEN hippocampal dopamine release will be restored to wild-type levels during spatial memory tasks, as measured by microdialysis HPLC, using P301S tau transgenic mice treated with GSK3β inhibitors versus vehicle controls

pending conf: 0.50

Expected outcome: Hippocampal extracellular dopamine concentrations will increase to ≥80% of wild-type levels in GSK3β inhibitor-treated P301S mice, accompanied by restored VTA-hippocampal theta synchronization on optogenetic recordings during spatial memory tasks

Falsified by: If pharmacological reduction of tau phosphorylation fails to restore hippocampal dopamine release or VTA-hippocampal circuit function despite successful lowering of phospho-tau levels, the hypothesis that tau pathology is the primary driver of dopaminergic dysfunction in this circuit would be disproven

Method: P301S MAPT transgenic mice (3-4 months old) will receive chronic GSK3β inhibitor treatment (lithium 10mg/kg or AR-A014418 10mg/kg) via osmotic minipump for 4 weeks. In vivo microdialysis in ventral hippocampus combined with behavioral testing (Morris water maze) will assess dopamine release. Optogenetic multiphoton imaging will measure VTA-hippocampal theta synchronization. Western blot and immunohistochemistry will confirm phospho-tau reduction (AT8, AT180 epitites)

IF monoamine oxidase (MAO) activity is inhibited selectively in VTA neurons of P301S tau mice THEN tau hyperphosphorylation at AT8 epitopes and microtubule destabilization will be significantly reduced specifically in VTA dopaminergic neurons, using primary VTA neuron culture transfected with P301L MAPT and treated with MAO inhibitors (clorgyline or selegiline)

pending conf: 0.50

Expected outcome: MAO inhibition will reduce phospho-tau (AT8) immunoreactivity by ≥60% in P301L-transfected VTA neurons, restore microtubule integrity demonstrated by acetylated tubulin normalization, and improve vesicular monoamine transporter 2 (VMAT2) trafficking to axon terminals by ≥50% as measured by live-cell imaging of fluorescently-tagged VMAT2

Falsified by: If MAO inhibition fails to reduce tau hyperphosphorylation or restore microtubule stability in VTA neurons despite confirmed MAO inhibition (measured via H2O2 production assays), this would falsify the proposed mechanism that MAO-derived ROS is the primary driver of tau pathology in these neurons

Method: Primary embryonic VTA neurons will be cultured and transfected with human P301L MAPT-EGFP. Neurons will be treated with MAO-A inhibitor (clorgyline, 10μM) or MAO-B inhibitor (selegiline, 10μM) or combined MAO inhibitor. Reactive oxygen species will be measured using Amplex Red assay. Tau phosphorylation will be assessed via AT8 immunocytochemistry and ELISA. Microtubule stability will be quantified via acetylated tubulin/tyrosinated tubulin ratio. VMAT2-mCherry trafficking will be tracked by liv

Knowledge Subgraph (138 edges)

▸ Show 10 more

PVALB→Alzheimer's diseaseSST→alzheimer_s_diseasePVALB→alzheimer_s_diseaseBDNF→alzheimer_s_diseasePVALB/SST→neuroscienceSST interneurons→Entorhinal cortex layer IIGamma oscillation disruption→Alzheimer's diseaseamyloid accumulation→PV+ interneuron dysfunctionamyloid accumulation→PV+ interneuronsSST→Alzheimer's disease

biomarker for (1)

gamma collapse→early MCI

catalyzes (1)

choline_acetyltransferase→cholinergic_signaling

causal extracted (2)

sess_ext_h-var-58e76ac310_20260428_050154→processedsess_ext_h-var-3b982ec3d2_20260428_045746→processed

causes (8)

tau pathology→SST interneuron dysfunctionSST interneuron dysfunction→accelerated tau propagationSST interneuron dysfunction→gamma desynchronizationoptogenetic gamma stimulation→tau pathology reductionTau pathology→SST interneuron dysfunction

▸ Show 3 more

Tau pathology→Tau propagationPV+ interneuron dysfunction→gamma collapsegamma collapse→hippocampal-cortical disconnect

causes (CaMKII enhancement promotes dendrite ramification ) (1)

CaMKII→dendrite ramification

causes (CaMKII-dependent process that promotes spine gener) (1)

CaMKII→spine generation

causes (NMDA receptors mediate synaptic depression in amyl) (1)

NMDA receptors→synaptic depression

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

VIP interneuron stimulation→pyramidal cell disinhibition

causes (loss of natural sensory input leads to degeneratio) (1)

natural sensory input loss→cholinergic circuit degeneration

causes (optogenetic activation selectively restores gamma ) (1)

optogenetic activation of PV interneurons→gamma oscillation restoration

causes (optogenetic activation selectively restores theta ) (1)

optogenetic activation of SST interneurons→theta oscillation restoration

causes (selective modulation of GluN2B-containing NMDA rec) (1)

GluN2B modulation→thalamocortical synchronization

causes (selective noradrenaline depletion exacerbates syna) (1)

noradrenaline depletion→synaptic deficits

causes (specifically disrupt parvalbumin-positive interneu) (1)

amyloid-β oligomers→PV interneurons

causes (specifically disrupt somatostatin-positive interne) (1)

amyloid-β oligomers→SST interneurons

causes (tau pathology spreads from locus coeruleus to hipp) (1)

tau pathology→hippocampal circuit dysfunction

co associated with (19)

BDNF→SSTCAMK2A→CHATCAMK2A→VIPCAMK2A→GRIN2BCHAT→VIP

▸ Show 14 more

CHAT→GRIN2BCAMK2A→MAPTCHAT→MAPTMAPT→VIPGRIN2B→MAPTBDNF→PVALBGRIN2B→VIPBDNF→CA3BDNF→CA1CAMK2A→PVALB/SSTCHAT→PVALB/SSTGRIN2B→PVALB/SSTMAPT→PVALB/SSTPVALB/SST→VIP

co discussed (14)

RAB5→TREM2RAB7→TREM2APP→GAD1GAD1→PSEN1BDNF→PSD95

▸ Show 9 more

APOE4→BDNFBDNF→CSF1RBDNF→TREM2HDAC→PSD95APP→PSD95AQP4→MAPTAPOE→TFEBCDK5→MAPKAQP4→TREM2

disrupts (1)

MAPT→hippocampal_circuit

dysfunction causes (1)

thalamocortical_circuit→cognitive_impairment

encodes (4)

CHAT→choline_acetyltransferaseGRIN2B→GluN2B_receptorMAPT→tau_proteinCAMK2A→CaMKII_protein

enhances (2)

gamma oscillations at 40Hz→glymphatic clearancegamma oscillations (40Hz)→glymphatic clearance

expressed in (3)

VIP→VIP_interneuronsPVALB→PV_interneuronsSST→SST_interneurons

generates (4)

PV_interneurons→gamma_oscillationsSST_interneurons→theta_oscillationsPVALB→gamma_oscillationSST→theta_oscillation

implicated in (7)

PVALB→neurodegenerationh-cd60e2ec→neuroscienceh-f8316acf→neuroscienceh-23b94ed8→neuroscienceh-62c78d8b→neuroscience

▸ Show 2 more

h-a635d4e5→neuroscienceh-7110565d→neuroscience

inhibits (1)

tACS→EC layer II SST interneurons

investigated in (4)

diseases-psp→h-var-6612521a02diseases-corticobasal-syndrome→h-var-9c0368bb70diseases-ftd→h-var-3b982ec3d2diseases-vascular-cognitive-impairment→h-var-6612521a02

involved in (3)

SST→gabaergic_interneuron_networksPVALB→prefrontal_inhibitory_circuitsBDNF→hippocampal_neurogenesis_and_synaptic_plasticity

modulates (12)

VIP_interneurons→default_mode_networkGluN2B_receptor→thalamocortical_circuitGRIN2B→thalamocortical_synchronygamma-frequency stimulation→tau pathologyGamma frequency stimulation→Alzheimer's disease pathology

▸ Show 7 more

Optogenetics→SST interneuron modulationClosed-loop tACS→Gamma entrainmentPV+ interneuron activity→excitatory transmissionclosed-loop tFUS→PV+ interneuron activitygamma oscillations (40Hz)→microglial phagocytosisgamma oscillations (40Hz)→excitatory transmissiontranscranial focused ultrasound (tFUS)→deep brain structures

participates in (2)

SST→GABAergic interneuron networksPVALB→Prefrontal inhibitory circuits

promotes (1)

CaMKII_protein→synaptic_plasticity

propagates through (1)

tau_protein→locus_coeruleus_hippocampus_pathway

regulates (5)

SST→gamma_oscillationSST interneurons→gamma oscillationsSST interneurons→Gamma oscillationsgamma oscillations (40Hz)→hippocampal-cortical connectivityPVALB→PV+ interneurons

studied in (3)

SST→neurosciencePVALB→neuroscienceBDNF→neuroscience

targets (2)

h-a635d4e5→VIPBDNF→Alzheimer's disease

therapeutic target (2)

SST→Alzheimer's diseasePVALB→Alzheimer's disease

therapeutic target for (2)

40Hz gamma entrainment→early MCIPV+ interneuron activity→Alzheimer's disease

Mechanism Pathway for MAPT

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    MAPT["MAPT"] -->|disrupts| hippocampal_circuit["hippocampal_circuit"]
    MAPT_1["MAPT"] -->|associated with| neuroscience["neuroscience"]
    MAPT_2["MAPT"] -->|encodes| tau_protein["tau_protein"]
    CAMK2A["CAMK2A"] -->|co associated with| MAPT_3["MAPT"]
    CHAT["CHAT"] -->|co associated with| MAPT_4["MAPT"]
    MAPT_5["MAPT"] -->|co associated with| VIP["VIP"]
    GRIN2B["GRIN2B"] -->|co associated with| MAPT_6["MAPT"]
    MAPT_7["MAPT"] -->|co associated with| PVALB_SST["PVALB/SST"]
    AQP4["AQP4"] -->|co discussed| MAPT_8["MAPT"]
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style hippocampal_circuit fill:#81c784,stroke:#333,color:#000
    style MAPT_1 fill:#ce93d8,stroke:#333,color:#000
    style neuroscience fill:#ef5350,stroke:#333,color:#000
    style MAPT_2 fill:#ce93d8,stroke:#333,color:#000
    style tau_protein fill:#4fc3f7,stroke:#333,color:#000
    style CAMK2A fill:#ce93d8,stroke:#333,color:#000
    style MAPT_3 fill:#ce93d8,stroke:#333,color:#000
    style CHAT fill:#ce93d8,stroke:#333,color:#000
    style MAPT_4 fill:#ce93d8,stroke:#333,color:#000
    style MAPT_5 fill:#ce93d8,stroke:#333,color:#000
    style VIP fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B fill:#ce93d8,stroke:#333,color:#000
    style MAPT_6 fill:#ce93d8,stroke:#333,color:#000
    style MAPT_7 fill:#ce93d8,stroke:#333,color:#000
    style PVALB_SST fill:#ce93d8,stroke:#333,color:#000
    style AQP4 fill:#ce93d8,stroke:#333,color:#000
    style MAPT_8 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 MAPT — PDB 5O3L Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Circuit-level neural dynamics in neurodegeneration

neuroscience | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance

Score: 0.96 · GRIN2B

Closed-loop transcranial focused ultrasound targeting EC-II SST intern

Score: 0.96 · SST

Closed-loop optogenetic targeting PV interneurons to restore theta-gam

Score: 0.95 · PVALB

Closed-loop transcranial focused ultrasound to restore hippocampal gam

Score: 0.91 · CCK

Gamma entrainment therapy to restore hippocampal-cortical synchrony

Score: 0.90 · SST

→ View all analysis hypotheses

Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 13

✗ Opposing Evidence 4

Mechanistic Analysis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PVALB in Early MCI

Critical Evaluation of Mechanistic Rationale

1. Foundational Claim: PV+ Interneurons as Gamma Pacemakers

Rigorous Skeptic's Critique: tFUS + 40Hz Gamma Entrainment Targeting PVALB in Early MCI

1. Weakest Assumptions

A. Mechanistic Specificity of tFUS → Ion Channel Cascade

Translational Feasibility Assessment

Hypothesis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PV+ Interneuron Dysfunction in Early MCI

1. Target Druggability and Accessibility Assessment

Synthesized Assessment: Closed-Loop tFUS with 40Hz Gamma Entrainment for Early MCI

Five-Dimensional Scoring

Price History

Clinical Trials (5) Relevance: 68%

📚 Cited Papers (18)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

Origin

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (130)

Dependency Graph (1 upstream, 0 downstream)

Linked Experiments (9)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (4)

Knowledge Subgraph (138 edges)

accelerates (1)

activates (5)

associated with (15)

biomarker for (1)

catalyzes (1)

causal extracted (2)

causes (8)

causes (CaMKII enhancement promotes dendrite ramification ) (1)

causes (CaMKII-dependent process that promotes spine gener) (1)

causes (NMDA receptors mediate synaptic depression in amyl) (1)

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

causes (loss of natural sensory input leads to degeneratio) (1)

causes (optogenetic activation selectively restores gamma ) (1)

causes (optogenetic activation selectively restores theta ) (1)

causes (selective modulation of GluN2B-containing NMDA rec) (1)

causes (selective noradrenaline depletion exacerbates syna) (1)

causes (specifically disrupt parvalbumin-positive interneu) (1)

causes (specifically disrupt somatostatin-positive interne) (1)

causes (tau pathology spreads from locus coeruleus to hipp) (1)

co associated with (19)

co discussed (14)

disrupts (1)

dysfunction causes (1)

encodes (4)

enhances (2)

expressed in (3)

generates (4)

implicated in (7)